SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:research.chalmers.se:d041bd0b-8270-474a-844f-e2082b95f084"
 

Sökning: onr:"swepub:oai:research.chalmers.se:d041bd0b-8270-474a-844f-e2082b95f084" > Six-week follow-up ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00008655naa a2200769 4500
001oai:research.chalmers.se:d041bd0b-8270-474a-844f-e2082b95f084
003SwePub
008171010s2016 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:52522da9-80a4-4fdf-936a-5de599dada06
009oai:gup.ub.gu.se/236143
009oai:DiVA.org:oru-56364
009oai:prod.swepub.kib.ki.se:133167372
0247 a https://research.chalmers.se/publication/2361432 URI
0247 a https://doi.org/10.3109/23744235.2015.10895932 DOI
0247 a https://lup.lub.lu.se/record/80346662 URI
0247 a https://gup.ub.gu.se/publication/2361432 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-563642 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1331673722 URI
040 a (SwePub)cthd (SwePub)lud (SwePub)gud (SwePub)orud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a for2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Gaines, Hansu Karolinska Institutet,Public Health Agency of Sweden, Solna, Sweden; Dept Med, Infect Dis Unit, Karolinska Institute, Stockholm, Sweden; Dept Infect Dis, Karolinska Univ Hosp, Stockholm, Sweden4 aut
2451 0a Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy
264 c 2015-09-28
264 1b Informa UK Limited,c 2016
520 a In 2014 the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy (RAV) conducted a review and analysis of the state of knowledge on the duration of follow-up after exposure to human immunodeficiency virus (HIV). Up until then a follow-up of 12 weeks after exposure had been recommended, but improved tests and new information on early diagnosis motivated a re-evaluation of the national recommendations by experts representing infectious diseases and microbiology, county medical officers, the RAV, the Public Health Agency, and other national authorities. Based on the current state of knowledge the Public Health Agency of Sweden and the RAV recommend, starting in April 2015, a follow-up period of 6 weeks after possible HIV-1 exposure, if HIV testing is performed using laboratory-based combination tests detecting both HIV antibody and antigen. If point-of-care rapid HIV tests are used, a follow-up period of 8 weeks is recommended, because currently available rapid tests have insufficient sensitivity for detection of HIV-1 antigen. A follow-up period of 12 weeks is recommended after a possible exposure for HIV-2, since presently used assays do not include HIV-2 antigens and only limited information is available on the development of HIV antibodies during early HIV-2 infection. If pre- or post-exposure prophylaxis is administered, the follow-up period is recommended to begin after completion of prophylaxis. Even if infection cannot be reliably excluded before the end of the recommended follow-up period, HIV testing should be performed at first contact for persons who seek such testing.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
653 a hiv follow-up window period
653 a prophylaxis
653 a hiv-2
653 a hiv-1
7001 a Albert, Janu Karolinska Institutet,Swedish Reference Group for Antiviral Therapy,Karolinska University Hospital,Dept Microbiol Tumor & Cell Biol, Karolinska Institute, Stockholm, Sweden; Dept Clin Microbiol, Karolinska Univ Hosp, Stockholm, Sweden; Swedish Reference Grp Antiviral Therapy, Stockholm, Sweden4 aut
7001 a Axelsson, Mariau Folkhälsomyndigheten,Public Health Agency of Sweden,Public Health Agency of Sweden, Solna, Sweden4 aut
7001 a Berglund, Torstenu Karolinska Institutet4 aut
7001 a Gisslén, Magnus,d 1962u Gothenburg University,Göteborgs universitet,University of Gothenburg,Swedish Reference Group for Antiviral Therapy,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine,Swedish Reference Grp Antiviral Therapy, Stockholm, Sweden; Dept Infect Dis, Sahlgrenska Acad, Univ Gothenburg, Gothenburg, Sweden4 aut0 (Swepub:gu)xgissm
7001 a Sonnerborg, A.u Karolinska Institutet,Swedish Reference Group for Antiviral Therapy,Karolinska University Hospital,Dept Infect Dis, Karolinska Univ Hosp, Stockholm, Sweden; Dept Clin Microbiol, Karolinska Univ Hosp, Stockholm, Sweden; Swedish Reference Grp Antiviral Therapy, Stockholm, Sweden; Div Clin Microbiol, Dept Lab Med, Karolinska Institute, Stockholm, Sweden4 aut
7001 a Blaxhult, Andersu Karolinska Institutet4 aut
7001 a Bogdanovic, Gordanau Karolinska universitetssjukhuset,Karolinska University Hospital,Dept Clin Microbiol, Karolinska Univ Hosp, Stockholm, Sweden4 aut
7001 a Brytting, Mariau Folkhälsomyndigheten,Public Health Agency of Sweden,Public Health Agency of Sweden, Solna, Sweden4 aut
7001 a Carlander, Christinau Karolinska Institutet4 aut
7001 a Flamholc, Leou Lund University,Lunds universitet,Enheten för infektionssjukdomar,Forskargrupper vid Lunds universitet,Infectious Diseases Research Unit,Lund University Research Groups,Swedish Reference Group for Antiviral Therapy,Swedish Reference Grp Antiviral Therapy, Stockholm, Sweden; Dept Infect Dis, Skåne Univ Hosp, Lund Univ, Malmö, Sweden4 aut0 (Swepub:lu)inf-lfl
7001 a Follin, Peru Västra Götalandsregionen,Region Västra Götaland,The County of Västra Götaland,Dept Communicable Dis Control & Prevent, Region Västra Götaland, Gothenburg, Sweden4 aut
7001 a Haggar, Axanau Socialstyrelsen,National Board of Health and Welfare,Socialstyrelsen / Swedish National Board of Health and Welfare,Natl Board Hlth & Welf, Stockholm, Sweden4 aut
7001 a Hagstam, Peru Lund University,Lunds universitet,Infektionsmedicin,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Infection Medicine (BMC),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Dept Communicable Dis Control & Prevent, Malmö, Sweden4 aut0 (Swepub:lu)infek-ph
7001 a Johansson, Marcus,d 1975u Kalmar County Hospital,Dept Clin Microbiol & Infect Dis, Kalmar Cty Hosp, Kalmar, Sweden4 aut0 (Swepub:cth)kf95020
7001 a Navér, Larsu Karolinska Institutet,Karolinska University Hospital,Swedish Reference Group for Antiviral Therapy,Swedish Reference Grp Antiviral Therapy, Stockholm, Sweden; Dept Pediat, Karolinska Univ Hosp, Stockholm, Sweden; Dept Clin Sci Intervent & Technol, Karolinska Institute, Stockholm, Sweden4 aut
7001 a Persson Blom, Jennyu Swedish Reference Group for Antiviral Therapy,Swedish Work Environment Authority, Stockholm, Sweden4 aut
7001 a Samuelson, Agnetau Karolinska Institutet4 aut
7001 a Ström, Helena,d 1985u Socialstyrelsen,National Board of Health and Welfare,Socialstyrelsen / Swedish National Board of Health and Welfare,Natl Board Hlth & Welf, Stockholm, Sweden4 aut
7001 a Sundqvist, Martinu Region Örebro län,Clin Microbiol, Örebro University Hospital, Örebro, Sweden4 aut0 (Swepub:oru)mist
7001 a Svedhem Johansson, Veronicau Karolinska Institutet4 aut
7001 a Tegmark Wisell, Karinu Karolinska Institutet,Public Health Agency of Sweden, Solna, Sweden4 aut
7001 a Tegnell, Andersu Karolinska Institutet,Public Health Agency of Sweden, Solna, Sweden4 aut
7001 a Thorstensson, Rigmoru Karolinska Institutet,Public Health Agency of Sweden, Solna, Sweden4 aut
7102 a Karolinska Institutetb Public Health Agency of Sweden, Solna, Sweden; Dept Med, Infect Dis Unit, Karolinska Institute, Stockholm, Sweden; Dept Infect Dis, Karolinska Univ Hosp, Stockholm, Sweden4 org
7730 t Infectious Diseasesd : Informa UK Limitedg 48:2, s. 93-98q 48:2<93-98x 2374-4235x 2374-4243
8564 u http://dx.doi.org/10.3109/23744235.2015.1089593y FULLTEXT
8564 u http://www.ncbi.nlm.nih.gov/pubmed/26414596?dopt=Abstracty FULLTEXT
8564 8u https://research.chalmers.se/publication/236143
8564 8u https://doi.org/10.3109/23744235.2015.1089593
8564 8u https://lup.lub.lu.se/record/8034666
8564 8u https://gup.ub.gu.se/publication/236143
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-56364
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:133167372

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy